- $7.86bn
- $6.29bn
- 47
- 27
- 49
- 36
Annual balance sheet for Vaxcyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | 2025 December 31st | |
|---|---|---|---|---|---|
| Period Length: | — | — | — | — | — |
| Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Cash and Equivalents | |||||
| Short Term Investments | |||||
| Cash and Short Term Investments | 246 | 931 | 1,080 | 1,747 | 1,561 |
| Net Total Receivables | — | — | — | 20.3 | 21.4 |
| Prepaid Expenses | |||||
| Total Current Assets | 256 | 943 | 1,096 | 1,788 | 1,627 |
| Gross Property, Plant And Equipment | |||||
| Accumulated Depreciation | |||||
| Net Property, Plant And Equipment | 35.9 | 31.6 | 111 | 270 | 373 |
| Long Term Investments | |||||
| Other Long Term Assets | |||||
| Total Assets | 324 | 1,006 | 1,408 | 3,511 | 3,003 |
| Accounts Payable | |||||
| Accrued Expenses | |||||
| Notes Payable / Short Term Debt | |||||
| Total Other Current Liabilities | |||||
| Total Current Liabilities | 28.7 | 40.5 | 145 | 140 | 206 |
| Total Long Term Debt | |||||
| Total Debt | |||||
| Total Other Liabilities | |||||
| Total Liabilities | 40.3 | 52.6 | 167 | 205 | 317 |
| Non Redeemable Preferred Stock | |||||
| Common Stock | |||||
| Additional Paid In Capital | |||||
| Retained Earnings (Accumulated Deficit) | |||||
| Other Equity | |||||
| Total Equity | 284 | 954 | 1,240 | 3,306 | 2,686 |
| Total Liabilities & Shareholders' Equity | 324 | 1,006 | 1,408 | 3,511 | 3,003 |
| Total Common Shares Outstanding |